T cell therapy of B-CLL lymphoma against CD20 alternative splice variant: in vitro experiments T cell therapy of B-CLL lymphoma
Archives of Advances in Biosciences,
Vol. 12 No. 3 (2021),
10 Tir 2021
,
Page 81-91
https://doi.org/10.22037/aab.v12i3.35823
Abstract
Introduction: Cancer immunotherapy has become a major player in modern oncology. In immunotherapy, immune cells selectively recognize and kill cancerous cells; this way, many side effects of chemotherapy and radiotherapy are reduced. One of the immunotherapy methods is the T cell therapy, which is based on the use of T cells with determined antigenic specificity for cancer cells. The search for unique tumor antigens which are specific to malignant cells and have the ability to stimulate cellular immunity is one of the main targets of malignancies treatment.
Materials and methods: D393-CD20 is an alternative splicing form of the CD20 surface receptor, which lacks 168 nucleotides in exons 3 to 7 of the CD20 sequence. D393-CD20 peptide is merely expressed on cancerous B cells, such as Burkitt’s lymphoma (BL), DLBCL and B-CLL. In this study we isolated and expanded a CD8+ T lymphocyte specific clone for a D393-CD20 antigen to examine the effect on B-CLL cell line. To this end, we evaluated the impact of cytotoxic T cells upon D393-CD20 antigen, expressed on malignant B cells. We also evaluated the ratio of apoptosis using flow cytometry and MTT.
Results: Results suggest that targeting D393-CD20 antigen with specific CD8+ T lymphocytes is very effective in preventing tumor cells growth.
Conclusion: Targeting D393-CD20 can be a proper choice for B-cell lymphoma immunotherapy.
- T cell therapy, B-CLL lymphoma CD20, Alternative splice variant, In vitro
How to Cite
References
Boffetta P. Epidemiology of adult non-Hodgkin lymphoma. Ann Oncol. 2011; 22(4): 27–31.
Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015; 90:447–460.
Gilles Salles, Martin Barrett, Robin Foà and et al. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther. 2017; 34(10): 2232–2273.
Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol. 2013;88(9):803–816.
Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005; 23(18):4117–26.
Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol.2006 May; 7(5):379-91.
Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28(27):4184–90.
Michael C. Milone1, Vijay G. Bhoj. The Pharmacology of T Cell Therapies. Mol Ther Methods Clin Dev. 2018 16; 8: 210–221.
Finn O. J. Cancer immunology. New England Journal of Medicine. 2008; 358(25):2704–2715.
Gabriele D’Errico, Heather L. Machado. A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet. Clinical and Translational Medicine. 2017; 6(1): p. 3.
Topalian S.L., Muul L.M., Solomon D., Rosenberg S.A. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Methods. 1987; 102(1):127–141.
Sitaru C,Thiel J. The need for markers and predictors of Rituximab treatment resistance. Exp Dermatol. 2014 Apr; 23(4):236-7.
Henry C, Deschamps M, Rohrlich P-S, et al. Identification of an alternative CD20 transcriptvariant in B-cell malignancies coding for a novelprotein associated to rituximab resistance. Blood. 2010 Mar 25; 115(12):2420-9.
Gamonet C, Ferrand C, Colliou N, et al. Lack of expression of an alternative CD20 transcript variant in circulating B cells from patients with Pemphigus. Exp Dermatol. 2014; 23 (1):66–7.
Small GW, McLeod HL, Richards KL. Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells. Peer J .2013; 1(10): e31.
Godet Y, Fabre E, Dosset M, Lamuraglia M, et al. Analysis of spontaneous tumor-specific CD4 Tcell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res Off J Am Assoc Cancer Res. 2012; 18(10):2943–53.
Chegni H, Hassan ZM, Nisini R, Ebrahimi M, Sabouni F. Preliminary in vitro effects of CD8+ T lymphocyte specific for the CD20 alternative splicing D393-CD20 peptide expressed on Burkitt lymphoma cells. Asian Pacific journal of cancer prevention: APJCP. 2019;20(8):2563.
Chegni, H., Hassan, Z., Nisini, R., Ebrahimi, M., & Sabouni, F. (2018). T Cell Therapy of Burkitt’s Lymphoma in Nude Mice Model Tumorized with Ramos Cell Line. Journal of clinical & cellular immunology, 09.
Mariotti S, Nisini R.Generation of Human T cell Clones.Methods in Molecular Biology, 2009;514(6):65-93.
Nikolova, M, Echchakir, H, Wechsler J, Boumsell L, Bensussan A. Bagot, M. Isolation of a CD8alphaalpha+ CD4- tumour T-cell clone with cytotoxic activity from a CD4+ CD8- cutaneous T-cell lymphoma. Br J Dermatol 2003; 148(1):24-9.
Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med. 1955; 102(2):157-177.
Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319(25):1676-1680.
Forget MA, Haymaker C, Hess KR, Meng YJ,et al . Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.Clin Cancer Res. 2018; 24(18):4416-4428.
Owens GL, Price MJ, Cheadle EJ, Hawkins RE, Gilham DE, Edmondson RJ. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells. Cancer Immunol Immunother. 2018; 67(10):1519-1531.
Zhang L, Vlad A, Milcarek C, Finn OJ. Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms.Cancer Immunol Immunother CII . 2013;62:423–35.
Lin J, Lin L, Thomas DG, et al. Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants. Clin Cancer Res off J Am Assoc Cancer Res 2004; 10(17):5708–16.
Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev 2003; 17(4):419–37.
Celay J, Lozano T, Concepcion AR, Beltrán E, Rudilla F, García-Barchino MJ ,et al: Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms. Haematologica. 2018 Jun; 103(6):1065-1072.
Jun-ichi Kobayashi, Toshihiko Torigoe, Yoshihiko Hirohashi,Satomi Idenoue, Akihiro Miyazaki,Akira Yamaguc:Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cellepitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients. Journal of Translational Medicine 2009; 7:1
Charline Vauchy, Clementine Gamonet, Christophe Ferrand, Etienne Daguindau, et al: CD20 alternative splicing isoform generates immunogenic CD4helper T epitopes. Int. J. Cancer. 2014: 137(1):116–126.
Clémentine Gamonet, Elodie Bole‑Richard, Aurélia Delherme, et al. New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. .Bio Med Central .2016; 5:7
Benjamin B,et al : Postulated Mechanisms of Resistance of B-Cell Non-Hodgkin Lymphoma to Rituximab Treatment Regimens: Strategies to Overcome Resistance. Seminoncol. 2014;41(5):667-77.
- Abstract Viewed: 238 times
- PDF Downloaded: 200 times